---
input_text: "Phytomedicines (medicines derived from plants) for sickle cell disease.
  BACKGROUND: Sickle cell disease, a common recessively inherited haemoglobin disorder,
  affects people from sub-Saharan Africa, the Middle East, Mediterranean basin, Indian
  subcontinent, Caribbean and South America. It is associated with complications and
  a reduced life expectancy. Phytomedicines (medicine derived from plants in their
  original state) encompass many of the plant remedies from traditional healers which
  the populations most affected would encounter. Laboratory research and limited clinical
  trials have suggested positive effects of phytomedicines both in vivo and in vitro.
  However, there has been little systematic appraisal of their benefits. This is an
  update of a Cochrane Review first published in 2004, and updated in 2010, 2013,
  and 2015. OBJECTIVES: To assess the benefits and risks of phytomedicines in people
  with sickle cell disease of all types, of any age, in any setting. SEARCH METHODS:
  We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies
  Trials Register, the International Standard Randomised Controlled Trial Number Register
  (ISRCTN), the Allied and Complimentary Medicine Database (AMED), ClinicalTrials.gov
  and the World Health Organization (WHO) International Clinical Trials Registry Platform
  (ICTRP).Dates of most recent searches: Cochrane Cystic Fibrosis and Genetic Disorders
  Haemoglobinopathies Trials Register: 10 April 2017; ISRCTN: 26 July 2017; AMED:
  24 August 2017; ClinicalTrials.gov: 02 August 2017; and the WHO ICTRP: 27 July 2017.
  SELECTION CRITERIA: Randomised or quasi-randomised trials with participants of all
  ages with sickle cell disease, in all settings, comparing the administration of
  phytomedicines, by any mode to placebo or conventional treatment, including blood
  transfusion and hydroxyurea. DATA COLLECTION AND ANALYSIS: Both authors independently
  assessed trial quality and extracted data. MAIN RESULTS: Two trials (182 participants)
  and two phytomedicines Niprisan  (also known as Nicosan ) and Ciklavit  were included.
  The Phase IIB (pivotal) trial suggests that Niprisan  was effective in reducing
  episodes of severe painful sickle cell disease crisis over a six-month period (low-quality
  evidence). It did not affect the risk of severe complications or the level of anaemia
  (low-quality evidence). No serious adverse effects were reported. The single trial
  of Cajanus cajan (Ciklavit ) reported a possible benefit to individuals with painful
  crises (low-quality evidence), and a possible adverse effect (non-significant) on
  the level of anaemia (low-quality evidence). AUTHORS' CONCLUSIONS: While Niprisan\
  \  appeared to be safe and effective in reducing severe painful crises over a six-month
  follow-up period, further trials are required to assess its role in the management
  of people with sickle cell disease and the results of its multicentre trials are
  awaited. Currently no conclusions can be made regarding the efficacy of Ciklavit
  . Based on the published results for Niprisan  and in view of the limitations in
  data collection and analysis of both trials, phytomedicines may have a potential
  beneficial effect in reducing painful crises in sickle cell disease. This needs
  to be further validated in future trials. More trials are required on the safety
  and efficacy of phytomedicines used in managing sickle cell disease."
raw_completion_output: |-
  primary_disease: Sickle cell disease
  medical_actions: Administration of phytomedicines; blood transfusion; hydroxyurea treatment
  symptoms: Severe painful crises; episodes of severe painful sickle cell disease crisis; risk of severe complications; level of anaemia
  chemicals: Niprisan; Nicosan; Ciklavit; Cajanus cajan
  action_annotation_relationships: Administration of phytomedicines TREATS severe painful crises IN Sickle cell disease; Niprisan (also known as Nicosan) TREATS episodes of severe painful sickle cell disease crisis IN Sickle cell disease; Niprisan PREVENTS risk of severe complications IN Sickle cell disease; Niprisan PREVENTS level of anaemia IN Sickle cell disease; Ciklavit (with Cajanus cajan) TREATS severe painful crises IN Sickle cell disease; Ciklavit PREVENTS level of anaemia IN Sickle cell disease
prompt: |+
  Split the following piece of text into fields in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Ciklavit PREVENTS level of anaemia IN Sickle cell disease

  ===

extracted_object:
  primary_disease: MONDO:0011382
  medical_actions:
    - Administration of phytomedicines
    - MAXO:0000756
    - hydroxyurea treatment
  symptoms:
    - Severe painful crises
    - episodes of severe painful sickle cell disease crisis
    - risk of severe complications
    - level of anaemia
  chemicals:
    - Niprisan
    - Nicosan
    - Ciklavit
    - Cajanus cajan
  action_annotation_relationships:
    - subject: Administration
      predicate: TREATS
      object: severe painful crises
      qualifier: MONDO:0011382
      object_qualifier: severe
      subject_extension: phytomedicines
    - subject: <Niprisan (also known as Nicosan) therapy>
      predicate: <TREATS>
      object: <painful sickle cell disease crisis>
      qualifier: <Sickle cell disease>
      subject_qualifier: <>
      object_qualifier: <severe>
      subject_extension: <Niprisan (also known as Nicosan)>
      object_extension: <severe>
    - predicate: PREVENTS
      object: risk of severe complications
      qualifier: MONDO:0011382
      subject_extension: Niprisan
    - predicate: PREVENTS
      object: level of anaemia
      qualifier: MONDO:0011382
      subject_extension: Niprisan
    - predicate: TREATS
      object: severe painful crises
      qualifier: MONDO:0011382
      subject_qualifier: with Cajanus cajan
      object_qualifier: severe
      subject_extension: Ciklavit
    - predicate: PREVENTS
      object: level of anaemia
      qualifier: MONDO:0011382
      subject_extension: Ciklavit
named_entities:
  - id: MONDO:0011382
    label: sickle cell disease
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:81579
    label: erythropoietin
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:35480
    label: analgesics
  - id: CHEBI:33281
    label: antibiotics
  - id: MAXO:0001077
    label: Splenectomy
  - id: MAXO:0000756
    label: Blood transfusion
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: HP:0001297
    label: Stroke
  - id: HP:0002863
    label: Myelodysplastic syndrome
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:82594
    label: Ferritin
  - id: MONDO:0000984
    label: thalassemia
  - id: MONDO:0018881
    label: myelodysplastic syndrome
  - id: HP:0002140
    label: Ischemic Stroke
  - id: MONDO:0005380
    label: avascular necrosis
  - id: MAXO:0009047
    label: total hip replacement
  - id: HP:0010885
    label: avascular necrosis
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: CHEBI:41879
    label: dexamethasone
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:9168
    label: sirolimus
  - id: CHEBI:8764
    label: mycophenolate mofetil
  - id: HP:0012531
    label: Pain
  - id: MAXO:0000515
    label: Extracorporeal life support
  - id: HP:0001708
    label: Right ventricular failure
  - id: HP:0033515
    label: opioid dependence
  - id: MONDO:0005632
    label: Acute chest syndrome in sickle cell disease
  - id: HP:0001945
    label: fever
  - id: HP:0001878
    label: Hemolytic anemia
  - id: CHEBI:6121
    label: ketamine
  - id: CHEBI:17303
    label: morphine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0031274
    label: hypovolemic shock
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: HP:0100512
    label: Vitamin D deficiency
  - id: CHEBI:27300
    label: Vitamin D
  - id: CHEBI:28940
    label: Cholecalciferol
  - id: CHEBI:29016
    label: arginine
  - id: CHEBI:18211
    label: citrulline
  - id: CHEBI:3638
    label: chloroquine
  - id: CHEBI:50733
    label: nutritional supplements
  - id: MONDO:0005570
    label: Blood disorders
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0002204
    label: Pulmonary embolus
  - id: HP:0100626
    label: end-stage liver disease
  - id: MONDO:0016363
    label: Iron overload diseases
  - id: HP:0012532
    label: Chronic pain
  - id: HP:0012432
    label: Chronic fatigue
  - id: MAXO:0010203
    label: echocardiography
  - id: HP:0002870
    label: obstructive sleep apnoea (OSA)
  - id: HP:0000520
    label: Proptosis
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000058
    label: pharmacological treatment
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: HP:0002878
    label: Acute respiratory failure
  - id: HP:0012594
    label: Microalbuminuria
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003774
    label: End-stage renal disease
  - id: CHEBI:35457
    label: angiotensin-converting enzyme inhibitor
  - id: MAXO:0000652
    label: angiotensin-converting enzyme inhibitor therapy
  - id: HP:0000112
    label: kidney disease
  - id: MAXO:0000457
    label: Pain management
  - id: HP:0001903
    label: Anemia
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0000827
    label: serum ferritin measurement
  - id: HP:0001875
    label: neutropenia
  - id: CHEBI:4356
    label: <desferrioxamine (DFO)
  - id: CHEBI:17941
    label: deferiprone (DFP)
  - id: CHEBI:49005
    label: deferasirox (DFX)
  - id: CHEBI:38157
    label: iron chelators
  - id: CHEBI:68554
    label: deferiprone
  - id: CHEBI:9144
    label: silymarin
  - id: MAXO:0000750
    label: conditioning regimens (fludarabine-thiotepa-treosulfan, busulfan-cyclophosphamide)
  - id: CHEBI:82557
    label: treosulfan
  - id: HP:0100602
    label: preeclampsia
  - id: HP:0001622
    label: preterm delivery
  - id: HP:0001511
    label: intrauterine growth restriction
  - id: CHEBI:50858
    label: corticosteroids
  - id: MAXO:0000618
    label: fluid replacement therapy
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0100639
    label: erectile dysfunction
  - id: CHEBI:71940
    label: Tadalafil
  - id: CHEBI:71942
    label: PDE5 inhibitors
  - id: MONDO:0019740
    label: Acquired thrombotic thrombocytopenic purpura (aTTP)
  - id: CHEBI:24261
    label: Glucocorticoids
  - id: MAXO:0000194
    label: Opioid therapy
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:35705
    label: immunosuppressive agents
  - id: HP:0003326
    label: Myalgia
  - id: HP:0002027
    label: Abdominal pain
  - id: HP:0002315
    label: Headache
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:46195
    label: Acetaminophen
  - id: CHEBI:47381
    label: Diclofenac
  - id: HP:0000832
    label: Primary hypothyroidism
  - id: HP:0011787
    label: Central hypothyroidism
  - id: CHEBI:18248
    label: Iron
  - id: CHEBI:30660
    label: Thyroxine
  - id: HP:0001342
    label: Hemorrhagic strokes
  - id: HP:0002326
    label: Transient ischemic attack
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome
  - id: HP:0001923
    label: hemolysis (reticulocytosis)
  - id: MONDO:0800385
    label: Iron overload
  - id: CHEBI:6456
    label: Lidocaine
  - id: CHEBI:75008
    label: <visual analog pain scale (VAS)>
  - id: CHEBI:41264
    label: busulfan (Bu)
  - id: HP:0025322
    label: Venous occlusive disease (VOD)
  - id: MONDO:0005399
    label: Venous thromboembolism (VTE)
  - id: HP:0002094
    label: dyspnea
  - id: MONDO:0007885
    label: Osteonecrosis of the Femoral Head (AVNFH)
  - id: HP:0000969
    label: Oedema
  - id: HP:0006554
    label: Acute Liver Failure
  - id: HP:0002098
    label: Respiratory distress
  - id: MAXO:0001175
    label: liver transplantation
  - id: MAXO:0010033
    label: umbilical cord blood transplantation
  - id: MAXO:0000068
    label: transplantation
  - id: CHEBI:17334
    label: penicillin
  - id: MAXO:0000066
    label: oxygen supplementation
  - id: HP:0002202
    label: pleural effusions
  - id: CHEBI:25805
    label: oxygen
  - id: HP:0002791
    label: alveolar hypoventilation
  - id: HP:0001395
    label: Liver fibrosis
  - id: MAXO:0035078
    label: Pulmonary function testing
  - id: HP:0001944
    label: dehydration
  - id: HP:0011105
    label: fluid overload
  - id: CHEBI:25107
    label: Magnesium
  - id: CHEBI:32599
    label: Magnesium sulphate
  - id: HP:0008209
    label: Premature ovarian insufficiency (POI)
  - id: HP:0011675
    label: Arrhythmias
  - id: HP:0012418
    label: Hypoxia
  - id: MAXO:0000118
    label: immunizations
  - id: MONDO:0100470
    label: Asthma
  - id: HP:0001627
    label: Cardiac abnormalities
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:16480
    label: nitric oxide
  - id: CHEBI:63533
    label: GnRH agonist
  - id: MAXO:0010314
    label: lung computed tomography
